Literature DB >> 14975732

Characterization and identification of the inhibitory domain of GDF-8 propeptide.

Man-Shiow Jiang1, Li-fang Liang, Shusheng Wang, Tamara Ratovitski, James Holmstrom, Christopher Barker, Ronald Stotish.   

Abstract

GDF-8 is a negative regulator of skeletal muscle mass. The mechanisms which regulate the biological activity of GDF-8 have not yet been elucidated. Analogous to the TGF-beta system, GDF-8 propeptide binds to and inhibits the activity of GDF-8. In these studies, we define the critical domain of the GDF-8 propeptide necessary for inhibitory activity. Two molecules of GDF-8 propeptide monomer inhibit the biological activity of one molecule of GDF-8 homodimer. Although the propeptide contains N-linked glycosylation when synthesized in mammalian cells, this glycosylation is not necessary for the inhibition of GDF-8. Taking advantage of the bacterial expression system, we express and purify GDF-8 propeptide which retains full inhibitory activity. To define the functional regions of the propeptide, we express a series of truncated GST-propeptide fusion proteins and examined their inhibitory activity. We observe that fusion proteins containing the C-terminal region (amino acid residues 99-266) are very stable, but do not exhibit inhibitory activity; while fusion proteins containing the N-terminal region (amino acid residues 42-115) are labile but contain essential inhibitory activity. The data suggest that the C-terminal region may play a role in the stability of the GDF-8 propeptide and that the inhibitory domain is located in the region between amino acids 42 and 115.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14975732     DOI: 10.1016/j.bbrc.2004.01.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  48 in total

1.  The K153R variant in the myostatin gene and sarcopenia at the end of the human lifespan.

Authors:  Marta González-Freire; Gabriel Rodríguez-Romo; Catalina Santiago; Natalia Bustamante-Ara; Thomas Yvert; Félix Gómez-Gallego; José A Serra Rexach; Jonatan R Ruiz; Alejandro Lucia
Journal:  Age (Dordr)       Date:  2010-03-23

2.  Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice.

Authors:  Kentaro Takayama; Tomo Asari; Mariko Saitoh; Kei Nirasawa; Eri Sasaki; Yoshimi Roppongi; Akari Nakamura; Yusuke Saga; Takahiro Shimada; Hiroaki Ikeyama; Akihiro Taguchi; Atsuhiko Taniguchi; Yoichi Negishi; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2019-05-28       Impact factor: 4.345

3.  A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength.

Authors:  Phonepasong Arounleut; Peter Bialek; Li-Fang Liang; Sunil Upadhyay; Sadanand Fulzele; Maribeth Johnson; Mohammed Elsalanty; Carlos M Isales; Mark W Hamrick
Journal:  Exp Gerontol       Date:  2013-07-04       Impact factor: 4.032

4.  Changes in skeletal muscle and tendon structure and function following genetic inactivation of myostatin in rats.

Authors:  Christopher L Mendias; Evan B Lynch; Jonathan P Gumucio; Michael D Flood; Danielle S Rittman; Douglas W Van Pelt; Stuart M Roche; Carol S Davis
Journal:  J Physiol       Date:  2015-02-25       Impact factor: 5.182

5.  Myostatin activation in patients with advanced heart failure and after mechanical unloading.

Authors:  Isaac George; Lawrence T Bish; Gayathri Kamalakkannan; Christopher M Petrilli; Mehmet C Oz; Yoshifumi Naka; H Lee Sweeney; Simon Maybaum
Journal:  Eur J Heart Fail       Date:  2010-03-27       Impact factor: 15.534

6.  A large bioactive BMP ligand with distinct signaling properties is produced by alternative proconvertase processing.

Authors:  Takuya Akiyama; Guillermo Marqués; Kristi A Wharton
Journal:  Sci Signal       Date:  2012-04-03       Impact factor: 8.192

7.  Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Chandramohan Kattamuri; Kristof Nolan; Huaying Zhao; Yisrael Sidis; Henry T Keutmann; Thomas B Thompson
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

8.  Cytotoxic aggregation and amyloid formation by the myostatin precursor protein.

Authors:  Carlene S Starck; Andrew J Sutherland-Smith
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

9.  Association of the K153R polymorphism in the myostatin gene and extreme longevity.

Authors:  Nuria Garatachea; Tomàs Pinós; Yolanda Cámara; Gabriel Rodríguez-Romo; Enzo Emanuele; Giovanni Ricevuti; Letizia Venturini; Alejandro Santos-Lozano; Catalina Santiago-Dorrego; Carmen Fiuza-Luces; Thomas Yvert; Antoni L Andreu; Alejandro Lucia
Journal:  Age (Dordr)       Date:  2013-01-25

10.  Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer.

Authors:  Sameer S Bajikar; Chun-Chao Wang; Michael A Borten; Elizabeth J Pereira; Kristen A Atkins; Kevin A Janes
Journal:  Dev Cell       Date:  2017-11-20       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.